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ABSTRACT 
 Treatments using a patient’s own T cells to target cancer have applied advances in 
genetic engineering and cancer immunotherapy as the basis for a powerful, targeted cell-
based therapy. Tumor-infiltrating lymphocytes and T cells that have been genetically 
modified to express cancer antigen-specific receptors—such as T cell receptors (TCRs) 
and chimeric antigen receptors (CARs)—leverage the innate targeted cytotoxicity of T 
cells against cancer. Despite promising results in clinical trials, these therapies have 
elicited serious and sometimes fatal responses. These toxicities include killing of healthy 
tissue expressing lower levels of antigen, as well as an overstimulation of the immune 
response called cytokine release syndrome. These outcomes reflect the double-edged 
nature of T cell-based therapies: the same powerful capability that makes them strong 
therapeutic candidates can become fatal if modified cells are left to their own devices.  
T cell therapies would greatly benefit from the development of tools that enable 
doctors to have bedside control over a cell’s behavior and truly respond to each patient’s 
needs. The work of this thesis aims to develop genetic circuits that control T cell activity. 
This platform has been adapted to control when CARs are expressed and at what level. In 
contrast to the current approach where patients are treated to one therapeutic “state,” 
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these genetic circuits will allow doctors to decide between multiple states defined by 
CAR expression through the addition of a drug. These circuits contain memory such that 
long-term administration of the drug is not required to maintain a change. I have designed 
an ON switch and an OFF switch to control when a CAR is expressed, and an 
EXPRESSION switch to increase CAR expression. I characterized the performance of 
these circuits to demonstrate their dynamics over time, as well as their ability to control T 
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1.1 Adoptive T cell therapies for cancer 
The immune system takes on many threats to the body, scanning and responding 
to the presence of foreign antigens. T cells contain the ability to engage in targeted 
cytotoxicity, relying on major histocompatibility complexes (MHC) on the surface of 
antigen presenting cells (APC) to present short protein sequences called epitopes from 
potential threats within the cell. T cell receptors (TCRs) scan these MHC-epitope 
complexes to determine whether there is a threat present, and if so, will trigger T cell 
activation and killing of the infected cell. These mechanisms enable T cells to assess the 
vast array of entities present within the body and target non-self entities. 
While cancer is a disease borne out of our own cells and does not always involve 
the presence of foreign pathogens, T cells are able to target cancer cells as well. Indeed, 
tumors employ several strategies to suppress the ability of the immune system to fight 
against cancerous cells (1), ranging from outcompeting T cells for nutrients to releasing 
molecules that increase the presence of regulatory T cells (2) and decrease the presence 
of cytotoxic T cells (3-5). Strategies have been developed to magnify the activity of a 
patient’s immune system against cancer, either with cytokine drugs that promote T cell 
proliferation (6-8) or by targeting these immunosuppressive mechanisms (9-12). 
Checkpoint blockers like the anti-programmed cell death 1 (PD-1) drug Nivolumab and 
the anti-cytotoxic T-lymphocyte protein 4 (CTLA4) drug Ipilimumab help to block 
immunosuppressive signals that are upregulated in the tumor microenvironment (13-15), 




checkpoint blockers, they are also accompanied by concerns over potentially toxicity, 
which can arise when the checkpoint blocker becomes overly effective such that the 
immune system’s actions are too strong for the body to handle (16).  
Additional work has demonstrated that T cells themselves may be a promising 
therapeutic agent. Patients who were treated with hematopoietic stem cell transplant 
(HSCT) to replenish bone marrow post-chemotherapy demonstrated a lower rate of a 
relapse, a graft-versus-tumor response that has been exhibited against several cancers 
including acute myeloid leukemia and non-Hodgkin’s lymphoma and is attributed to the 
presence of fresh T cells that are able to target the cancer cells (17-19). However, this 
response is also correlated to graft-versus-host disease (GVHD) wherein donor T cells 
attack the host's tissue. Thus, while T cells have a demonstrated capability to kill cancer 
cells, avoiding GVHD requires developing strategies based around a patient’s own T 
cells.  
Significant work has also been put in to create more direct cell-based approaches 
towards targeting cancer. In one approach, T cells that have been able to penetrate a 
patient’s tumor are extracted, expanded, and re-infused back into the patient (Figure 
1.1a) (20, 21). This tumor-infiltrating lymphocyte (TIL) approach has demonstrated 40-
50% clinical response against metastatic melanoma (22-24). However, this approach is 
limited by the availability of TILS within a given patient, as well as the uncertainty of 
whether they will be able to target cancer cells (25). 
New approaches use genetic engineering to program a patient’s own T cells to 




been engineered to target cancer markers (Figure 1.1b). The first type of receptor is the 
cancer antigen-specific TCR, which can recognize cancer epitopes presented on MHCs 
(27, 28). The second type of receptor is the chimeric antigen receptor (CAR), a synthetic 
receptor comprised of a extracellular single chain variable fragment (scFv) connected to 
intracellular T cell signaling domains involved in driving activation and proliferation (29, 
30).  
In choosing an scFv that binds to cancer antigens, CARs are able to detect and 
trigger T cell activation against cancer cells through the signaling domains. These 
signaling domains include the activating CD3ζ-domain and, in later generations of CAR 
design, proliferative domains such as CD28 and 4-1BB. The choice in proliferative 
domain has been demonstrated to influence engineered T cell behavior such as 
therapeutic onset time and T cell persistence (31-35). These differences can in turn affect 
patient outcomes, reflecting the complexity that even a single domain can introduce into 
engineered systems. 
Therapies utilizing these receptors will differ in the types of targets they can 
recognize: TCR-based therapies will be MHC-restricted and thus can only recognize 
peptide epitopes bound to the MHC complex. However, this approach also ensures that 
TCR therapies can assess the presence of cancer markers expressed within the cell, as 
long as these markers have peptide epitopes that are eventually presented on the cell 
surface. CAR-based therapies can target a wider range of markers as they are not limited 
to peptides. However, these markers must be molecules that are naturally expressed at the 




To implement both TIL and engineered receptor therapies, T cells are first 
collected from the patient—either from the tumor (TILs) or from the patient’s blood 
(engineered receptors) (Figure 1.1a). In engineered receptor therapies, the extracted T 
cells are then modified using either viral or transposon-based methods (36) to express the 
desired receptor. The desired T cell population is expanded ex vivo. Prior to infusion, the 
patient must first undergo an immunodepletion procedure. This lymphodepletion process 
creates favorable conditions in the patient for the therapy, possibly through the deletion 
of regulatory T cells and less competition for nutrients (18). T cells are then infused into 
the patient. 
In addition to the clinical trial results described above using TILs against 
metastatic melanoma, both engineered receptors have been tested in clinical trials. In one 
clinical trial using an engineered TCR-approach to treat patients with melanoma, 33% of 
patients responded (27). And clinical trials utilizing CD19-specific CARs against B cell 
cancers have demonstrated tremendous results, leading to up to a 90% complete response 
rate in patients in multiple trials (31-34). These results have driven significant 
excitement, and several companies have been built (or invested significant amounts of 
time and money) on the promise of these synthetic receptors to harness the power of the 
immune system against cancer (37).  
However, there are still significant safety considerations that must be taken into 
account. One major challenge is the potential for “on-target, off-tumor” responses that 
result when T cells respond to target antigen present, sometimes at lower levels, on 




been fatal in one clinical where an ERBB2-specific CAR, which was meant to target 
colon cancer that had metastasized to the lungs and liver, began targeting healthy lung 
tissue that expressed lower levels of ERBB2 (39). The danger of “on-target, off-tumor” 
response is less prevalent for the use of CD19-specific CARs against B cell cancers, as 
CD19 is highly specific to B cells (40, 41). However, the likelihood of finding such a 
specific marker for all tissues or cancer cells is low, and expanding the use of CARs 
beyond the treatment of B cell cancers will require careful consideration of how to 
program cells to distinguish between cancer and healthy cells expressing the same 
marker. 
Cytokine release syndrome (CRS) can also pose a major safety challenge for this 
therapy (42). The immune system relies on a complex system of checks and balances to 
prevent it from responding too strongly against pathogens, posing more harm to the 
patient. CARs in particular instigate a strong response to antigens that has provoked the 
release of cytokines that accelerate the immune response to a potentially fatal level. In 
several clinical trials, CRS has resulted in severe symptoms that include high fever, 
hypotension, and hypoxia (34). To address these responses, patients are generally treated 
with immunosuppressive antibodies or steroids that dampen activity of the immune 
system. It is also possible to reduce the severity of CRS by adjusting the dosage of CAR-
bearing T cells infused into a patient (31). 
The safety considerations outlined above point to the dangerous aspects of what is 
otherwise the major advantage of cell-based therapies: the ability to engage in strong 




immense cost, both in terms of time and money, of cell-based therapies, which make it 
difficult to iterate this therapy over and over again until it meets a patient's individual 
needs. 
Synthetic biology approaches for adoptive T cell therapies 
T cell therapies would greatly benefit from the development tools that provide 
greater control over a cell’s behavior, enabling an already personalized therapy to be 
customizable towards a patient’s immediate and changing needs. Synthetic biology as a 
field is well-positioned for this kind of work, as advances in our understanding of a wide 
range of cells and organisms has allowed both the development of genetic engineering 
tools and strategies that program powerful controls over cell behavior (43-46). Adoptive 
T cell therapy has been a particularly exciting arena for synthetic biology approaches 
because it provides an opportunity to apply much of the work that has been done in 
engineering mammalian cells (44, 47) to the specific therapeutic challenge of regulating 
the immune system (48).  
Towards this end, many different tools have been developed to provide controls 
over T cell therapy. While they might all be the product of an explicitly synthetic biology 
source, they reflect an approach to mammalian engineering that has become increasingly 
the arena of synthetic biologists. These strategies are diverse, covering synthetic 
receptors, protein-based switches, genetic circuits, and genome editing tools that also 
enable control over a wide range of functions (Figure 1.2).  
CARs already reflect this potential as a synthetic receptor, demonstrating the 




cellular behavior. Further engineering of synthetic receptors has involved the 
development of an inhibitory CAR that—in contrast to the T cell-activating properties of 
the typical CAR—suppresses T cell activity when bound to the target antigen (49). This 
work has been mirrored in library approaches to identify the use of different proliferative 
domains and their ability to drive anti-tumor activity (35, 50).  
These synthetic receptors have been further designed to achieve particular 
therapeutic behaviors. Work done with combinatorial activation CAR systems (51, 52), 
“ON switch” CARs (53), and tunable receptor systems (54-56) have helped envisions 
systems that can increase the specificity of CARs or provide more spatiotemporal control 
over their activation. Non-CAR receptors have also been engineered to program a 
specified behavior into the T cell, such as the engineered G protein-coupled receptor 
RASSL that can drive small molecule-inducible chemotaxis of the T cell to a desired 
location (57, 58).  
Control switches and genetic circuits have also provided another layer of control. 
Drug-inducible kill switches such as iCaspase9 or herpes simplex virus-thymidine kinase 
(HSV-TK) allow inducible apoptosis in engineered T cells (59-64), a simple circuit that 
would enable a T cell therapy to be terminated if the patient exhibits severe side effects. 
This approach has been tested in vivo with CARs (59), and also in clinical trials for 
patients receiving stem cell transplants (62). In addition, doxycycline-inducible CARs 
(65), circuits that control T cell proliferation (66), and circuits that pause T cell activation 
(67) have provided alternate strategies to regulate T cell behavior in accordance with 




Other approaches to engineer T cells for cancer therapy target the chassis itself. 
For example, metabolic engineering approaches have been suggested in an attempt to 
bias the population of T cells towards particular subsets, some which may be 
therapeutically advantageous (68-70). Gene editing techniques have also been employed 
to knock out either HLA molecules (71) or TCR molecules (72) in T cells, enabling the 
development of “off-the-shelf” T cells that may reduce the cost and time of therapeutic 
implementation.  
While these technologies offer important forms of control over T cell behavior, 
their designs are accompanied by limitations. For example, while kill switches provide a 
vital control in cases where the T cells are toxic to the patient, completely shutting off the 
therapy may be an extreme response for patients who only require a slight modification 
of the therapy to abrogate negative reactions. Some approaches are also limited to certain 
types of therapy, such as the many CAR receptor designs that strictly provide added 
flexibility and control to CAR T cell therapy. In addition, certain drug-inducible systems 
like the “ON Switch” CAR require the drug to be continuously provided to maintain the 
ON state, which may be less ideal if permanent changes are required for a patient. While 
these approaches will advance the scope of potential T cell therapies, developing further 
technologies that are compatible with them may help to expand their use.   
1.2 Designing a genetic circuit for T cell therapy 
The objective of my work is to construct a generalized genetic circuit platform 
that enables drug-inducible control over the expression of genes of interest. The circuits I 




circuit that can stably alter the expression of genes within to create changes in overall cell 
behavior. I will adapt this design to create an ON switch, OFF switch, and EXPression 
level switch, which I hypothesize will allow for tunable control over T cell activity 
While I will demonstrate the application of these circuits to control the expression 
of CARs, these circuits will be compatible with all forms of T cell therapy, with potential 
applicability to other future cell-based therapies. The insights gained while constructing 
these CAR-based circuits will carry over to the construction of circuits that can control 
other features of the cell, and that—in the long term—may provide a set of design rules 
that enable doctors and engineers to refine T cell therapies for each particular patient. 
These circuits will be the basis of a dial that allows doctors to choose between two states 
of therapy. Chapter 2 will describe the design of the circuits, as well as well as the 
process for establishing a system that meets our desired performance criteria. 
1.3 Characterizing the performance of the genetic circuit 
 In chapter 3, I will demonstrate that the genetic circuits I have constructed are 
able to control CAR expression in T cells. I will characterize the dynamics of the switch 
over time, as well as demonstrate its ability to control T cell behavior by assessing 
changes in T cell activation. 
1.4 Defining parameters of control 
 In chapter 4, I will demonstrate that the genetic circuits contain memory such that 
when the inducer is removed from the cells, the cells are able to maintain any changes 





1.5 Advancing these designs into a platform for T cell therapies 
 In chapter 5, I will discuss the potential limitations in applying these circuits in a 
therapeutic setting, as well as some strategies that may help to overcome these 
challenges. I will also discuss strategies to extend the circuits I have designed and tested 







Figure 1.1 Adoptive T cell approaches for cancer immunotherapy.  
(a) Two general strategies exist to utilize a patient’s own T cells against cancer. In the first 
approach, tumor infiltrating lymphocytes (TILs) are extracted from the tumor, expanded ex vivo, 
and then transfused into the patient. In the second approach, cancer-targeting receptors are 
engineered and expressed in the T cell. The patient’s T cells are extracted from their blood, 
modified to express the receptor, expanded, and then transfused back into the patient. (b) 
Engineered receptors include cancer-targeting T cell receptors (TCRs) and chimeric antigen 
receptors (CARs). Engineered TCRs bind to cancer protein epitopes presented on the surface of a 
cell via the major histocompatibility complex (MHC). CARs can target a wider array of markers, 





Figure 1.2 Synthetic biology approaches to engineering T cell therapies. 
A number of synthetic biology approaches have been developed to engineer improved T cells for 
adoptive therapy. These approaches include synthetic receptors that introduce increased 
specificity or control, circuits that can alter T cell behavior, and genome editing and metabolic 






2.1 Establishing Design Criteria for Circuit  
The objective of my work is to design a genetic circuit that would increase the 
flexibility and control over T cell therapies. I envisioned this switch as one that would 
allow a doctor to choose between two states of therapy: an initial state (State 1) and a 
secondary state (State 2) that can only be accessed by the administration of a drug 
(Figure 2.1). This strategy allows for a more flexible and personalized application of 
adoptive T-cell therapy, effectively allowing for bedside tuning of the therapy in response 
to the patient’s needs. To design these circuits, I established three key criteria:  
 
(1) The circuits must be drug-inducible. It is conceivable to apply the changes 
described in some of the switches by applying the therapy in multiple rounds and 
using a different genetic modification each time until the therapy has met the 
patient’s needs. However, the lymphodepletion process required is strenuous for 
patients, making such a strategy both time-consuming and stressful. I envision the 
switches described as ones that can be controlled at bedside using the transient 
addition of a drug so that a doctor can easily change the therapy with minimal 
stress for the patient.  
 
(2) The circuits must demonstrate stable switching. T-cells undergo rapid 
proliferation upon activation, so it is important that the system we design provides 




rapid expansion. This requirement precludes the use of a switch where the second, 
drug-inducible state is expressed under a transcriptional promoter, as rapid 
proliferation leads to drug dilution. In addition, stable switching will ensure that 
continuous drug addition is not required to retain changes made to the T cell, 
making the changes easier to maintain.  
 
(3) The circuits must be lentivirus-compatible. Due to the use of lentiviral 
integration to express CARs stably in T-cells, we will use designs that are 
compatible with lentiviral integration.  
 
2.2 Establishing a Design and Testing Process 
In addition to establishing design criteria, it was important to establish a design 
process that would allow rapid testing of the many potential circuit components and 
designs. One of the goals of synthetic biology is to establish standardization, both in parts 
and process. With many engineering disciplines, the knowledge of certain key parameters 
and equations has allowed for some predictability when constructing larger works out of 
smaller, well-characterized pieces. Biology poses many challenges to this approach, as 
noise within and outside the cell can muddle the predictability attached to biological 
components, and unknown interactions can cause pieces to act in ways that are not 
predicted by their original behavior. Genetic parts may have varied effects on gene 
expression when arranged in different orders, proteins may lose certain functions when 




on the cell's behavior (74). 
The design process in synthetic biology has thus relied heavily on the design and 
construction of large numbers of system that cover a wide range of parameter space in the 
hopes of achieving one or two designs that yield the desired behavior. This approach will 
likely always be integral to the advancement of synthetic biology, relying on the rapid 
assembly and testing of parts to build systems that will become increasingly complex as 
we advance the types of controls we aim to design over cells. Rapid assembly has been 
aided greatly by advances in cloning techniques, particularly Gibson assembly to clone 
several segments of DNA together in one reaction.  
Rapid testing, on the other hand, can be more challenging and is reliant upon the 
choice in chassis. Compounded with the cost of mammalian cell work, testing can often 
become rate-limiting in designing circuits for therapeutic purposes. In mammalian cells, 
transient transfection to temporarily express plasmid DNA would be the ideal choice for 
rapid testing as it generally allows for characterization within 1-2 days of transfection. 
However, the efficiency of transient transfection varies across cell types, and T cells can 
be quite challenging for transfection. Chemical transfection reagents that are cheap, easy, 
and efficient in the human endothelial kidney (HEK) cell line are often much less 
successful in T cells. Indeed, electroporation or nucleofection is the preferred method of 
transient transfection of both the Jurkat T cell line, an immortalized cell line, and primary 
T cells that are derived from patient’s blood. However, electroporation efficiency in 
Jurkat T cells is still often mediocre, which is further inconvenienced by the high toxicity 




a large quantity of high quality DNA, both of which require significant set-up time that 
ultimately diminishes the usefulness of Jurkat transfection as a method of rapid testing. 
Instead of relying on the low-efficiency and intensive Jurkat transfection process, 
viral transduction is preferable to test circuit performance in T cells due to its ability to 
create cell lines that stably express circuit components. In addition, compatibility with 
lentiviral transduction is one of the key circuit design criteria due to its use in clinical 
implementations of adoptive T cell therapy, making it necessary to confirm that 
lentiviruses can be used to implement these circuits. However, the entire process of viral 
transduction takes about one week, a length of time that is unrealistic for the rapid 
turnover necessary for synthetic biology. And while it would be preferable to focus this 
viral work entirely on primary T cells, which is more clinically relevant than the Jurkat T 
cells, primary T cells require greater cost and time to maintain and transduce compared to 
Jurkat T cells. The challenges of efficiently transducing primary T cells necessitates 
selection or—as I conducted—sorting via flow cytometry, adding more time to the 
protocol. In addition, primary T cells must be stimulated to begin proliferation prior to 
testing, but their stimulated period and the number of times they can be stimulated is 
finite. This limit makes primary T cells difficult for rapid troubleshooting of issues 
related to viral transduction or T cell handling.    
To take advantage of the potential speed of transient transfection with the 
expression efficiency and clinical reality of viral transduction, I chose to combine 
experiments across multiple cell lines that would enable me to establish the viability of 




characterization in the next (Figure 2.2). I chose to test different parts of our circuits via 
transient transfection in HEK cells using the chemical transfection reagent 
polyethylenimine (PEI). This approach allowed for quick verification of expression of 
any fluorescently-tagged components, as well as confirmation of the functionality of 
certain proteins and drug induction systems. However, the high plasmid copy number, 
lack of genetic integration, and variability between cell lines limits the conclusions we 
can make from the HEK transfection results and the predictions for our T cell 
experiments.  
Instead, I used results from our HEK experiments to narrow down the constructs 
tested in Jurkat T cells, or to test components while they were also being integrated into 
Jurkat T cells. Jurkat T cell experiments were used to confirm that the circuits were 
compatible with lentiviral transductions and that the genetic circuits perform in T cells, at 
which point primary CD4+ T cells were used for characterization. This pipeline thus 
allowed me to quickly establish the viability of the circuit parts for use in mammalian 
cells while taking the time to create cell lines that enable more thorough characterization.  
2.3 Adapting a Recombinase-Based Stable Inversion Switch for T Cells 
Based on the design criteria and process outlined above, I used a recombinase-
based stable inversion switch, also called the FLEx switch (73). DNA recombinases are 
enzymes derived from bacteria and fungi that recognize pairs of DNA sequences that are 
30-40 base pairs long (Figure 2.3a). Examples of recombinases include the Cre 
recombinase, which detects and acts upon lox site, and the Flp recombinase, which acts 




recombinase will invert the DNA sequence between them (Figure 2.3b). This inversion 
is unstable as the recombinase sites are still present in the genome. When the recognition 
sites are oriented in the same direction, the recombinase will excise the sequence between 
them completely. By orienting recognition sites around either genes or promoters, we can 
control gene expression via recombinase activity.  
There are a number of features of recombinases that make them useful for 
mammalian cell engineering. Variants of lox and frt sites have been developed that allow 
their corresponding recombinase to detect and act upon multiple pairs of sites. These 
pairs can be selected to not interact with each (i.e. frt and its f3 variant will not recombine 
with each other), enabling the construction of more elaborate recombinase-based circuits. 
Because their non-mammalian origins increases the likelihood that they will act 
orthogonally to other processes in the cell, recombinases have been employed to great 
effect in mammalian cells. These applications include the use of recombinases in labeling 
cells (75), as well as the rapid design and construction of complex logic gates (76). 
The stable inversion FLEx switch was designed using the Cre/lox system to take a 
cell from an initial State 1 to a final State 2 upon recombinase activity, where the states 
are defined by the expression of certain genes (Figure 2.4a) (73). The switch works by 
having State 1 encoded in the sense orientation so that it is expressed in the cell. State 2 is 
in the antisense orientation, where it remains silent. When the recombinase acts on these 
sites, the switch will first undergo an unstable inversion step and followed by a stable 
excision step. In its final state, the State 1 is no longer encoded in the DNA, rendering it 




This recombinase-based FLEx stable inversion switch meets the three criteria I 
established earlier: 
 
(1) Recombinases can be made drug-inducible through a number of 
mechanisms, including transcriptional control (doxycycline, abscisic acid) 
(77-80), nuclear localization (tamoxifen) (81), and dimerization 
(rapamycin) (82, 83).  
 
(2) The stable inversion switch design exhibits stable switching due to the 
irreversible nature of the final State 2, which provides the system with 
memory. When the drug is added and the cell is driven to State 2, the cell 
will remain in that state even after the drug is removed. This trait ensures 
that continuous application of the drug is not required to maintain any 
changes to the cell over the long term.  
 
(3) The stable inversion switch is lentivirus compatible. Simpler 
recombinase-based circuits can and have been designed with the same 
effect as the stable inversion switch using transcription termination sites, 
and these sites can even be used to construct complex recombinase-based 
logic systems in mammalian cells. However, such sites interfere with virus 
production and are therefore incompatible with clinical settings that 




require transcriptional stop sites and is compatible with viral integration 
methods. 
 
This stable inversion switch has the potential to serve as a platform for control 
over many types of T cell therapies simply by slotting a gene or promoter of interest 
between recognition sites. I have adapted the FLEx stable inversion switch design to 
control the expression of a CAR gene, creating a genetic circuit that will enable bedside 
control over CAR-based therapies. These circuits include a stable ON and stable OFF 
switch (Figure 2.4b). In addition, I have designed an “Expression Level” (EXP) switch 
that affects the orientation of the human EF1α promoter relative to the CAR gene, stably 
taking cells from low expression to high expression of CAR. 
2.4 Adapting the FLEx switch for a tamoxifen-inducible FlpO 
The FLEx stable inversion switch was initially designed and implemented with 
the Cre/lox recombinase. However, while Cre is powerful and has demonstrated its 
applicability in a number of systems, it also known to be toxic (84, 85) in mammalian 
cells due to the presence of pseudo-loxP sites in the genome that may be targeted by the 
recombinase. This genotoxicity can be mitigated, but it requires careful tuning of Cre 
expression and activity (86).  
Based on the original stable inversion switch design and successful Cre induction 
in transient transfection HEK293 experiments, I tested the tamoxifen-inducible Cre 
recombinase to implement circuits in Jurkat T cells. This inducible recombinase system 




which localizes the recombinase to the cytoplasm where it is unable to interact with 
nuclear DNA (81). Upon induction with the drug tamoxifen, the recombinase is localized 
to the nucleus, where it is then able to act upon the switch. I integrated the CreERT2 
recombinase into Jurkat T cells along with an mCherry/GFP stable inversion switch that 
takes cells from expressing mCherry to GFP upon recombinase induction. This infection 
was done in two steps: first Jurkat T cells were transduced with the mCherry/GFP stable 
inversion switch virus, and infected cells were then transduced again with the CreERT2 
virus. 
In uninduced cells, viability remains around 82-83% cells, suggesting that there 
may be some basal CreERT2 activity that is also toxic to the cell (Figure 2.5). In cells 
induced with the tamoxifen metabolite 4-hydroxytamoxifen (4OHT), viability goes down 
to 36% within a week of induction, suggesting that Cre activity drove toxicity in cells. 
This decrease in cell viability is not sustainable for any therapeutic use of an engineered 
circuit. This toxicity did not appear in my previous transient transfection experiments 
testing Cre activity in HEK, as successful induction of transiently transfected cells can 
obscure issues of toxicity. Transient transfection allows a short testing time due to the 
dilution and degradation of the plasmid DNA encoding circuit components, which limits 
the ability to detect off-target effects that may take some time to build up. And the 
transfection process itself can be toxic, making it challenging to disentangle what process 
is driving cell death. 
In an attempt to salvage the Cre recombinase as an option for my circuits, I 




the stable inversion switch but not cause genotoxicity. In the first approach, I reduced the 
amount of virus containing the CreERT2 insert I added to the Jurkat T cells for viral 
transduction. The viability results in Figure 2.5 were the result of using 1 mL of virus 
with 500,000 cells. My hypothesis was that by reducing the amount of CreERT2 virus, 
there would also be a reduced probability of multiple copies becoming integrated into the 
genome, which would in turn reduce the total amount of recombinase present in the cell. 
While I did not quantify viral titer or CreERT2 expression, decreasing the amount of 
CreERT2 virus did correspond to greater viability 7 days post-induction (Figure 2.6a). 
Using the mCherry/GFP stable inversion switch, I was able to also observe the effect this 
decreased viability had on switch performance. While induced cells with all levels of 
CreERT2 virus demonstrated an increase in GFP expression within 3 days of induction, 
they all exhibited a loss of GFP expression by day 7. Tellingly, this reduction in GFP 
expression occurred even in cells exhibiting less toxicity. 
In addition to trying less virus, I also tried inducing recombinase activity for 
shorter periods of time. Similar to striving to find the right virus dosage, the objective 
with this approach was to find a certain period of induction that would be long enough to 
allow the recombinase to alter expression in the stable inversion switch, but short enough 
to minimize genotoxic activity. Still using 1 mL of the CreERT2 to infect cells, I induced 
cells on day 0. To induce cells for different durations, I washed the cells to remove 
4OHT. Induced cells still demonstrated a loss in viability and GFP expression. 
Interestingly, both the viability and GFP expression are similar for all of the induction 




on all sites within one day. Unfortunately, the tradeoff of this rapid activity is that 
genotoxic events also likely occur quickly. 
Both of these attempts to reduce Cre toxicity failed to find a successful strategy. 
Of course, there many other potential strategies I could have attempted: reduced promoter 
strength, double induction methods, reduced drug dosage, or even shorter induction 
duration periods—not to mention a combination of these different approaches. However, 
instead of exploring these myriad strategies, I chose to proceed with the Flp recombinase, 
a variant of the Flp recombinase, which has not had reported toxicity in the literature (88, 
89). I adapted the FLEx switch for the Flp recombinase by swapping the lox 
recombination sites for frt and f3 recombination sites. A similar Flp-based stable 
inversion switch has been designed for mammalian cells using other frt variant sites (90). 
To determine the best inducible version of Flp, I tested different drug-inducible 
systems with both Flp and its FlpO variant. These systems included the 4OHT-inducible 
nuclear localization system; a doxycycline-inducible transcriptional control system; a 
combined 4OHT/doxycycline-inducible system that combines nuclear localization and 
transcriptional control; and an abscisic acid-inducible transcriptional control system. 
Following the stated component testing workflow, I initially tested these inducible Flp 
recombinases in transiently transfected HEK293T cells to determine functionality with a 
stable inversion mCherry/GFP switch (Figure 2.7a). All inducible systems demonstrated 
some increase in GFP expression, though basal activity and dynamic range varied.  
As these experiments were conducted with transient transfection of HEK cells, 




functional in mammalian cells. When the 4OHT-inducible systems were moved into 
stable Jurkat T cells, their activity confirmed the limitations of HEK293T transfection 
data for my engineering purposes (Figure 2.7b). There are two key differences to note. 
The first difference is that FlpERT2, which had activity in HEK293T cells, had almost no 
observable activity in Jurkat T cells within one day of induction. The second is that 
FlpOERT2 had much lower basal activity when stably integrated in Jurkat T cells 
compared to the results in HEK293T cells. These differences could be the result of other 
processes that interfere with the expression or activity of the recombinases in T cells, but 
most importantly, the FlpOERT2 demonstrated promising activity. 
I chose to proceed with the FlpOERT2 system because of this performance in 
Jurkat T cells, as well as its ease of use. Transcriptionally-inducible systems like the 
doxycycline- and abscisic acid-inducible systems require the integration of both the drug-
inducible transcription factor and the promoter-recombinase cassette, which introduces 
more complexity into the circuit design.  FlpOERT2 can be encoded in one cassette, and is 
thus much easier to control. Tamoxifen is also an FDA-approved drug, which would 
facilitate implementation in clinics. 
2.5 Developing an integration strategy for primary T cells 
In addition to defining the components of the circuits, I also explored strategies to 
determine how to best implement the circuits in primary T cells. The stable inversion 
switch and inducible recombinase components are encoded on two separate viral vectors. 
Because viral transduction into primary T cells is time-consuming, requiring both large 




the amount of time and reagents required will be fundamental to creating more complex 
controls of therapeutic T cells that may require multiple viruses.  
I focused on creating an integration strategy that would require only one round of 
transduction. I tested two approaches. In one approach, which I called co-transfection, 
HEK293-T cells were transiently transfected with viral plasmids and inserts from the two 
different circuit components (inducible recombinase and stable inversion switch). This 
transfection would produce a mix of viruses: recombinase (+) viruses, switch (+) viruses, 
and in some cases, recombinase (+)/switch (+) viruses. In the other approach, which I 
called co-transduction, two separate batches of viruses would be produced, each 
containing one circuit component. I then took half of each batch of virus and mixed them 
1:1 prior to spinfection. The co-transfection method would be more ideal as it would 
require less virus and less DNA. 
I tested both methods to integrate the FlpOERT2 and stable inversion switch in 
primary CD4+ T cells, comparing the results to cells that were transduced with just one 
construct (Figure 2.8). While co-transduction and co-transfection both displayed low 
efficiency in expressing both constructs, particularly when compared to single-construct 
transduction, co-transduction appeared to perform slightly better. These transduction 
efficiencies improved in the development of later cell lines used in later chapters, likely 








Figure 2.1 Implementation of a 2 state switch for control of T cell therapy.  
This approach would enable a patient to begin their therapeutic regimen in an initial State 1. If the 
patient responds well to this therapeutic state, no changes need to be made. If some change be 
required, such as lower or higher activity, a doctor would be able to provide a drug that will 






Figure 2.2 Process for testing and implementing components of genetic circuits.  
This process allows for a balance between the rapid testing required to decide between many 
potential component, which is allowed with the HEK transient transfection, with the need to 






Figure 2.3 Recombinase-based excision or inversion of DNA.  
(a) Cre and FlpO recombinases recognize lox and frt sites and their variants respectively. (b) 
Recombinases either invert or excise DNA based on the relative orientation of recombinase sites. 
When sites are in opposite directions, the DNA encoded between the sites is unstably inverted. 






Figure 2.4 FlpO recombinase based FLEx switch design.   
(a) Mechanism of the 4OHT-inducible FLEx switch. Induction with 4OHT drives nuclear 
localization of the FlpO recombinase, initiating inversion and then excision upon the frt/f3 
recognition sites. By encoding genes representing State 1 and State 2 between the recognition 
sites, induction of FlpO activity stably shifts the cell from State 1 to State 2.  (b) Design of the 






Figure 2.5 Cre activation is toxic to Jurkat T cells.  
Inducation of CreERT2 activity with 4OHT in Jurkat T cells expressing a fluorescent stable 
inversion led to reduction in viability. A single sample was obtained from each induced or non-






Figure 2.6 Attempts to tune Cre activity did not reduce toxicity.  
(a) In cells with increasingly reduced CreERT2 viral loads, toxicity was also reduced. Decreased 
viability corresponded to a loss in GFP expression from the stable inversion switch. (b) In cells 
induced with fewer days, all induced cells demonstrated similar levels of toxicity and GFP 






Figure 2.7 Drug-inducible Flp and FlpO control GFP expression in an mCherry/GFP stable 
inversion switch. 
(a) Different drug-inducible forms Flp and its variant FlpO were tested in transiently transfected 
HEK cells. These induction systems included 4OHT (nuclear localization control), doxycycline 
(dox; transcriptional control), 4OHT/Dox (transcriptional and nuclear localization dual control), 
and abscisic acid (aba; transcriptional control). (b) FlpOERT2 demonstrates stronger activity in 





Figure 2.8 Co-transduction provided slightly improved transduction of two viruses in 
primary CD4+ T cells compared to co-transfection. 
Primary CD4+ T cells were transduced with either the stable inversion switch expressing an 
mCherry-tagged CAR, the inducible recombinase, or a combination implemented via the co-
transduction or co-transfection double integration methods. Numbers highlight in green are the 





3.1 Induction of recombinase activity drives changes in CAR expression 
To express and characterize the designed circuits, I transduced human primary 
CD4+ T cells with two viruses: one that contained a constitutively expressed FlpOERT2, 
and another expressing either the ON, OFF, or EXP switch. All switches were designed 
to control expression of an αHer2-CAR. Using the T2A-BFP marker, I sorted cells for 
FlpOERT2 expression. Cells were induced with 4OHT, and changes in CAR expression 
were observed via flow cytometry. I designed the EXP switch to control expression of a 
CAR directly conjugated to an mCherry fluorescent protein, which enabled easy 
visualization of CAR expression. For the ON and OFF switched, I used αHer2-CARs that 
contain a myc epitope marker in the ON and OFF switch, which allowed visualization of 
CAR expression via antibody staining without confounding questions of potential delays 
in degradation due to the mCherry protein. Results were gated for BFP+ expression to 
ensure all cells analyzed expressed the recombinase. 
All three circuits exhibited changes in αHer2-CAR expression in recombinase-
positive CD4+ T cells within one day of induction (Figure 3.1). The ON switch in 
particular demonstrated fast kinetics, reaching its maximal percentage of switched cells 
within one day. Meanwhile, OFF Switch cells demonstrated a loss in CAR+ cells within 
one day of induction, but it required six days to stabilize (<10% cells expressing CAR). 
The slower dynamics of the OFF Switch compared to the ON Switch is likely due to the 
need to degrade and dilute CAR expression, making the OFF switch more reliant upon 




The EXP Switch exhibits an increase in mean CAR expression across all 
recombinase-positive CD4+ primary T cells, though only approximately 20% of the cells 
express CAR. Indeed, all three circuits demonstrate that our populations are not 
homogenously expressing all components of the circuit. In addition to variations in 
recombinase and CAR expression (Figure 3.2), not all induced ON Switch cells express 
CAR (Figure 3.1). Nor do all uninduced OFF and EXP switch cells express CAR 
(Figure 3.1). This population heterogeneity is likely due to transduction inefficiency that 
limits successful integration of both the recombinase and switch viruses, which creates a 
mixture of four subpopulations (Recombinase-/Switch-, Recombinase+/Switch-, 
Recombinase+/Switch+, Recombinase-/Switch+). Based on available sorting capabilities, 
I was only able to sort cells for recombinase-positive expression. However, the ability to 
sort for both recombinase- and switch-positive cells might allow for greater homogeneity 
in engineered primary T cell populations. I integrated these circuits into Jurkat T cells, 
which generally exhibit greater ease of transduction, and observed populations with 
greater homogeneity (Figure 3.3). 
Two key markers of circuit performance are basal switching and incomplete 
switching. Basal switching corresponds to recombinase activity that occurs without drug 
induction, a trait that should be minimized to prevent undesired switching. Incomplete 
switching refers to the total fraction of cells that have not successfully switched at the end 
of the induction period. Because it is meant to be completely silent prior to induction, the 
ON switch is the best circuit to quantify basal activity. Approximately ~8% of ON 




FlpOERT2 activity (Figure 3.1). This basal level of CAR expression appears to be 
connected to a higher level of recombinase expression (Figure 3.2). Meanwhile, because 
it is meant to turn completely off, incomplete switching is most strictly quantified in the 
OFF switch, where less than 10% of cells still expressed CAR at the end of induction. 
Further analysis and computational modeling of the relationship between recombinase 
expression and both basal activity and incomplete switching could potentially aid in 
addressing these challenges. For example, if we can identify a threshold level of 
recombinase expression that—when exceeded—drives basal activity, we may potentially 
be able to sort those high-expressing cells out of the population. Similarly, if we can 
connect incomplete switching to a certain low level of recombinase expression, cells can 
be sorted appropriately. 
In addition to these markers of circuit activity, I observed high viability for 
induced primary CD4+ T cells over to the course of induction (Figure 3.4). The growth 
of the induced cells was also comparable to wild type cells, and together these results 
suggest that the genotoxicity of the FlpO recombinase is minimal. To the best of my 
knowledge, this is the first characterization of Flp toxicity in human T cells, and further 
work to assess toxicity—such as karyotyping—will help assess the potential for Flp, not 
just in my circuit design, but in other T cell engineering pursuits. This reduced toxicity—





3.2 Changes in CAR expression impact Jurkat NFAT signaling 
The objective of this work is not only to control gene expression, but also to 
control T cell behavior. In the instance of circuits controlling CAR expression, these 
induced changes in CAR expression are expected to alter T cell responses to antigen 
stimulation.  I quantified the activation of circuit-expressing T cells in both Jurkat and 
primary CD4+ T cells by stimulating them with plate-bound Her2 antigen.  
The nuclear factor of activated T cells (NFAT) transcription factors are involved 
in T cell activation (91), and a Jurkat T cell line has been previously created to express an 
engineered NFAT-GFP reporter (92). This line allows for easy visualization of T cell 
activation through flow cytometry measurements of GFP expression, and while this 
reporter is not a substitute for more rigorous methods of T cell activation quantification, 
it is a useful tool with my previously described use of Jurkat T cells as a fast check of 
circuit performance compared to the more time-intensive process of ELISAs.  
In Jurkat T cells exposed to plated Her2 protein, the changes in αHer2-CAR 
expression driven by the circuit corresponded to changes in NFAT-GFP activation 
(Figure 3.5). I observed that induced ON switch T cells, which express a CAR after 
4OHT-induction, can be activated with Her2. There was a low level of NFAT reporter 
expression at higher Her2 doses that suggests some basal CAR expression in uninduced 
cells, which could be due to the low level of basal recombinase activity. With the OFF 
switch, I observed that 4OHT-induced cells have low NFAT reporter activity when 
stimulated with Her2, corresponding to the loss in CAR expression. The remaining level 




which may result from factors such as inaccessibility to the integration site. These results 
are mirrored in ON and OFF switch CD4+ primary T cells that are activated 10 days after 
induction, where activation is measured via IL-2 production (Figure 3.5).  
For EXP-expressing Jurkat T cells, I observed that the increase in CAR 
expression after 4OHT induction led to a corresponding increase in NFAT-GFP 
expression (Figure 3.5). Interestingly, while I observed this effect for a low affinity 
Her2-CAR (C6.5G98A, KD = 3.2×10-7), when the expression level switch is applied to 
Her2-CARs with increased affinity (C6.5, KD = 1.6×10-8; C6MH3-B1, KD = 1.2×10-10; 
C6-B1D2, KD = 1.5×10-11) (30), there is little difference in NFAT-GFP activation level 
between uninduced and induced cells (Figure 3.6). These results suggest that T cell 
activation is dually modulated by the CAR expression level and its antigen-scFv affinity 
(Figure 3.6), corroborating similar observations by others (30, 52, 93, 94). Primary 
CD4+ T cells expressing the EXP switch also demonstrate an increase in IL-2 production 
when activated against Her2. Expression of IL-2 in uninduced EXP cells was low and 
similar to wild type, which may be due to a combination of the low CAR expression 
within the cells, the small population of cells expressing CAR overall, and the low 
affinity of the CAR. 
These results demonstrate the functionality of the stable inversion switches to 
control CAR activity. They also provided dynamic information about how the circuits 
perform, as well as confirmation that T cell behavior can in turn be controlled via drug-








Figure 3.1  FlpO can be used to create ON, OFF, and EXPression level switches for 
controlling CAR expression in human primary CD4+ T cells.  
Top Panel.  Time course data for the recombinase switches with or without drug addition 
(4OHT). Samples were obtained in triplicate from each induced or non-induced culture and then 
plotted as mean and standard deviation. The ON and OFF switches are presented as percent cell 
expressing the αnti-Her2 CAR.  The EXP switch is presented as the mean CAR expression level 
in arbitrary units (AU).  Bottom Panel.  The histogram of CAR expression level (AU) at different 
days after 4OHT addition.  Dashed vertical line illustrates the CAR expression level that is 
considered to be CAR positive for the ON and OFF switch, and low CAR expression level in the 





Figure 3.2 Basal FlpO activity is correlated with FlpO expression level in primary T cells.   
At high BFP level, which is correlated to FlpOERT2 expression, FlpO activity is observed 
without 4OHT.  This effect is most prominent for the ON switch. Data is representative of one 





Figure 3.3 CAR expression kinetics for the ON, OFF, and EXP switch in Jurkat T cells 
(Top Panel)  Time course data for the recombinase switches with or without drug addition 
(4OHT). Samples were obtained in triplicate from each induced or non-induced culture and then 
plotted as mean and standard deviation. (Bottom Panel)  The histogram of CAR expression level 
(AU) at different days after 4OHT addition.  Dashed vertical line illustrates the CAR expression 
level that is considered to be CAR positive for the ON and OFF switch, and low CAR expression 






Figure 3.4 Primary T cells with active FlpO the have the same viability as wild type T cells 
without any FlpO expression. 
Percentage of viable cells (Top panel) and cell concentration (Bottom Panel) as a function of time 
with or without 4OHT addition. Samples were obtained in triplicate from each induced or non-





Figure 3.5 Dose-response profile of an αHer2 CAR activation in T cells containing the 
recombinase switches.  
Jurkat T cells (Left panel) and human primary CD4+ T cells (Right panel) containing the ON, 
OFF, or EXP switch were exposed to 4OHT prior to CAR activation for 5 days (Jurkat, ON and 
OFF), 8 days (Jurkat, EXP), and 9 days (Primary CD4+, all).  The α-Her2 CAR was induced by 
different concentration of plate-bound Her2 protein.  A GFP NFAT transcription reporter and IL-
2 were measured for Her2 CAR Jurkat and primary T cell respectively. Cells were plated against 
Her2 antigen in triplicate, and both NFAT-GFP (arbitrary units, AU) and IL-2 (pg/mL) were 
plotted as mean and standard deviation. Significance in IL-2 production was determined by 





Figure 3.6 EXP level switch did not lead to measurable change in CAR activity for CARs 
with higher scFv antigen affinity.  
(Top Panel)  The addition of 4OHT led to an increase of CAR expression. Samples were obtained 
in triplicate from each induced or non-induced culture and then plotted as mean and standard 
deviation.   (Bottom Panel)  CAR activity was quantified using the NFAT GFP transcription 
reporter in Jurkat T cell. Cells were plated against Her2 antigen in triplicate and plotted as mean 





 4.1 Switch cells exhibit memory when drug is removed 
One of the key characteristics I described as a requirement for these genetic 
circuits was stable switching, which ensures that continuous drug addition will not be 
required to maintain any desired changes to the cell. Because State 2 of the stable 
inversion switch contains only two FlpO recognition sites that do not interact with each 
other, cells that have reached this state will not revert back to State 1. This memory is a 
unique feature of this circuit that has not be engineered in other CAR-controlling 
switches, and it ensures that removal of the drug will not affect changes made to the cells. 
Cells that have been switched on will stay on, cells that have switched off will stay off, 
and cells that now express more CAR will continue to express more CAR. 
To confirm that these circuits do contain memory, I washed human primary CD4+ 
T cells 2 days post-induction to remove 4OHT and then measured CAR expression 15 
days post-induction. In all three switches, CAR expression in washed cells remained the 
same as cells that had been continuously induced for 15 days (Figure 4.1). Removal of 
the drug thus did not affect the changes made to the cell, demonstrating the memory 
capacity of these circuits that makes stable switching possible. 
4.2 Tunability of switching can be driven by drug dosage and duration 
I initially described these circuits as a binary state: either the cell is in State 1 or 
State 2. However, it is possible that a therapy would benefit from achieving some level of 
activity in between those two states, requiring a finer level of adjustment than simply 




of tuning would provide even more powerful control compared to the original two-state 
system I described, allowing for a potentially more modulated level of T cell activity.  
To test whether this tuning is possible, I studied two strategies to modulate the 
level of switching. In the first approach, I adjusted the drug dosage, which would in turn 
affect the level of recombinase activity. I treated primary CD4+ T cells with a range of 
4OHT dosages and measured CAR expression 3, 6, and 9 days post-induction. The dose 
response profile of the ON and OFF switch demonstrates that the percentage of cells that 
switch states can indeed be modulated (Figure 4.2a). In addition, the mean level of CAR 
expression in the EXP switch can be tuned via drug dosage. 
These drug dosage results demonstrate that intermediate values of switching can 
be achieved by regulating recombinase activity. However, I would expect based on the 
recombinase and induction mechanism that if cells were exposed to even low levels of 
drug for a long enough time span, these cells would eventually become fully switched to 
State 2. Further investigation into the kinetics of drug delivery and induction will provide 
further information into how to use drug dosage to tune switch behavior and ultimately T 
cell activity. 
In addition to tuning T cell behavior via drug dosage, the capacity for memory in 
these circuits opens up the potential for another tunable parameter: induction duration. By 
adding the drug for different lengths of time, the FlpO recombinase will only be active on 
the switch for that designated duration. For a short enough drug duration, not all cells 
would be switched, and because the circuits contain memory, this mixed population 




composition can be tuned.  
This capacity is most apparent when induction duration was varied in Jurkat OFF 
Switch cells, where populations that were induced longer contained fewer CAR+ cells 
(Figure 4.2b, 4.3). The ON switch does not display this effect as strongly, though there 
does appear to be some correlation between increased duration and the percentage of 
cells that have switched ON. These results may be the effect of different switch dynamics 
inherent to the circuit, where the slower switching of the OFF switch could mean that 
there is a more distinct difference in CAR expression day-to-day to be engrained in the 
circuit memory. 
  This explanation could carry over the primary T cells, where cells induced for 
only 2 days expressed the same level of CAR as cells that had been induced longer. This 
result suggests that at 1 µM 4OHT, drug duration on the order of days does not tune CAR 
expression in primary T cells (Figure 4.1). These differences compared to Jurkat T cells 
could be the result of particular characteristics of the circuit (i.e. copy number or 
transduction efficiency) or the cells themselves (i.e. proliferation rates). However, it may 
be possible to apply the results of the drug dosage experiment to identify 4OHT 
concentrations that slow down switching in primary T cells to intermediate levels that 
will then enable drug duration tuning similar—or maybe even more distinct—than Jurkat 
T cells. Further in vivo work will also provide vital information about the relationship 
between drug dosage and duration, particular as both will be affected the 
pharmacokinetics of tamoxifen. In vivo work could also provide interesting results about 




could in turn inform the development of more refined therapeutic approaches. 
These results suggest a promising path to follow in advancing the use of these 
circuits in T cell therapies, while also providing further insight into FlpO activity in T 
cells that may aid in the design of future FlpO-based circuits. The results from these 
experiments are currently being used by our collaborator Dr. Jack Bowyer and Dr. 
Declan Bates at the University of Warwick, who are developing computational models of 
FlpO activity upon the stable inversion switch. With this combination of experimental 
and computational work, we will be able to better understand how to tune the behavior of 







Figure 4.1  Recombinase switches in primary T cells maintained CAR expression memory 
after the removal of the inducer. 
(a) Experimental work flow characterizing the switch circuit memory.  (b)  CAR expression from 
the ON, OFF, or EXP switch with or without washing the 4OHT after 2 days of 4OHT exposure. 
CAR expression was measured 15 days after the initial drug addition. Samples were obtained in 






Figure 4.2 The dose and exposure duration of 4OHT govern the CAR expression from the 
recombinase switches.   
(a) CAR expression as a function of 4OHT concentration for the ON, OFF, and EXP switch.  
Different lines represent the CAR expression at 3, 6 or 9 days after 4OHT exposure. (b) CAR 
expression as a function of 4OHT exposure duration.  Cells were washed at the indicated day 
after 4OHT exposure, and CAR expression was measured 14 days after the initial drug addition. 
Samples in (a) and (b) were obtained in triplicate from each induced or non-induced culture and 





Figure 4.3 CAR expression level can be stably regulated by the duration of 4OHT exposure 
in Jurkat T cells. 
The arrows indicate the different times when 4OHT was washed away from the sample. Samples 
were obtained in triplicate from each induced or non-induced culture and then plotted as mean 






5.1 Outcomes and potential challenges 
 I have presented a recombinase-based genetic circuit system that allows for 
increased control of primary T cell behavior. The circuits I have presented here are a 
lentiviral compatible system with memory capability such that continual addition of the 
drug is not required for maintenance of any desired changes to the cellular state. These 
switches can be used to turn a gene ON or OFF, as well as to stably alter the level of gene 
expression.  
Suboptimal recombinase activity 
 In making these circuits a viable option for therapeutic purposes, there are several 
challenges that must be considered for future. The performance of these circuits will 
require careful consideration for use in patients. The low levels of basal activity or 
incomplete switching may carry an unacceptable risk for certain therapeutic strategies. 
For example, if these circuits are being used to turn on expression of a highly active CAR 
whose expression is only desired as a last resort, low basal activity could be dangerous 
for the patient. Or in cases where expression of a certain gene must be completely shut 
off for safety reasons, the OFF switch may not be adequate. Indeed, the slow dynamics of 
the OFF switch may make it less ideal as a tool to combat toxicity, particularly compared 
to the rapid onset of inducible kill switches.  
 These challenges in basal activity and incomplete switching may be addressable 
by adding elements to the circuits. For example, integrating an inducible kill switch like 




safety switch that shuts off cells that are behaving undesirably without completely killing 
all cells (Figure 5.1a). In addition, as our results indicated, basal activity was connected 
to higher levels of FlpOERT2 expression. One interesting question for future 
computational and experimental work would be whether there is a specific level of 
FlpOERT2 expression that effectively shuts off basal activity, and whether it is possible to 
use tools like sorting or promoter engineering to achieve this level of recombinase 
expression. This question will also be necessary to explore in vivo, as tamoxifen 
pharmacokinetics may affect the dynamics of switching alongside basal or incomplete 
switching. 
Irreversibility 
 The questions of basal or incomplete switching are compounded by the 
irreversible nature of this circuit. Irreversibility as an inherent trait of the stable inversion 
switch enabled stable switching, one of the predetermined characteristics that these 
circuits were designed around. However, maintaining permanent changes may not be 
appropriate for all therapeutic strategies. Work in the Wong lab sought to take advantage 
of serine recombinases like PhiC whose activity differs from tyrosine recombinases like 
Cre and Flp, and whose effects can be reversed with the addition of a redirectionality 
factor (95). However, this work did not result in a viable circuit due to challenges in 
engineering the components. Memoryless circuits, such as ones based on drug-inducible 
transcription factors, may be ideal in cases where the safety or dynamics provided by 





 Another potential limitation of our circuits is the possible immunogenicity of 
FlpO, which is derived from yeast. Immunogenicity refers to the potential for the 
patient’s immune system to respond to a molecule. Because the immune system is 
designed to scan the body for foreign molecules that may pose a threat, engineering cells 
with components derived from other organisms can elicit an immunogenic response 
against the modified T cells (96). This response is a clear cause for concern in the 
development of synthetic biology and genetic engineering tools, many of which are 
otherwise promising in part because they are of non-human origin and may function 
orthogonally to other human cellular processes.  
 Immunogenic responses can be responsible for neutralizing engineered tools or 
clearing engineered cells from the body, preventing any therapeutic benefit (97-100). In 
the worst case, these responses can drive a systemic inflammatory responses that has 
been fatal (101). CARs themselves have demonstrated a potential immunogenic response, 
such as the case where CARs derived from murine antibodies initiated anaphylactic 
responses in a patient (102). CRISPR, which is dependent upon Cas9 homologs derived 
from bacteria that are known to infect humans at high frequencies, has inspired recent 
work identifying antibodies present in the population that can recognize to Cas9 (103). 
The potential for humans to have an adaptive immune response to the essential enzyme 
underlying CRISPR raises questions about how to balance its power as a gene editing 
tool with the need to avoid immunogenic responses, questions that are also important to 




 To mitigate transgene immunogenicity, one strategy is to leverage genome editing 
tools to eliminate the gene encoding B2M, an important component for antigen display 
through class I human leukocyte antigen (HLA) (104, 105).  This strategy has also been 
combined with HLA-E overexpression to reduce immunogenicity against pluripotent 
stem cells (106).  This approach would not only enable the development of “universal T 
cells” and provide a bank of “off-the-shelf” therapeutic T cells, it would enable the 
incorporation of genetic technologies comprised of proteins from diverse organisms. 
With greater understanding of how to implement these strategies, many engineered 
systems have the potential to be safely applied in cell-based therapies, including the 
circuits described in this work. 
5.2 Advancing the Stable Inversion Switch for Therapeutic Use 
The circuits I have designed and characterized in this work advance the 
development of controls over T cell behavior and provide insight into the development of 
FlpO-based circuits in T cells. These results illustrate not only the promise of the 
approach demonstrated here, they also provide a foundation to build further designs that 
will increase the safety and efficacy of T cell treatments. 
Controlling non-CAR genes 
While the circuits I described here have focused on using these circuits to control 
CAR expression, it is conceivable to apply them towards the control of a number of other 
genes. In fact, one of the potential advantages of this circuit is its adaptability to any state 
that can be defined by a gene. While success in synthetic biology is never guaranteed, 




it would be very easy to construct these circuits for control of other important factors that 
could in turn affect T cell behavior. This in turn provides options of control for other T 
cell therapies such as TILs or engineered TCR-expressing T cells. In addition, these 
circuits are compatible with other T cell engineering technologies, including the ones I 
discussed in Chapter 1. This compatibility makes these circuits powerful not just as a 
singular form of control over one or two genes, but as a potential bridge that can connect 
different T cell technologies to build a stronger and safer T cell for cancer therapies.   
One potential approach is to use these circuits to control the expression of 
cytokines like IL-2 (Figure 5.1b). IL-2 drugs like Proleukin are designed to overcome 
some of the challenges associated with the T cell microenvironment, stimulating T cell 
expansion and driving anti-tumor T cell responses (107). However, large doses of IL-2 
can lead drive an overly strong immune response and trigger systemic toxicity in the 
patients (108). The design of circuits that control IL-2 expression within a T cell would 
allow not only for localized production of IL-2, but finer control over when it is produced 
and at what level. This approach could also be attempted for other cytokines, creating a 
platform of stable cytokine-controlling circuits that could then be selected for a particular 
patient’s needs. 
Single-virus switches 
The circuits implemented in this work used two viruses to express the full 
circuitry. One virus contained the stable inversion switch, and the other virus contained 
the recombinase. While this double-virus approach was effective, it introduces added 




variability within the final population, as cells can belong to one of four populations: 
Switch (-)/Recombinase (-), Switch (+)/Recombinase (-), Switch (-)/Recombinase (+), 
and Switch (+)/Recombinase (+). This variability impedes the effectiveness of the 
switch across the population, as not all cells will be capable of making the switch, and 
may not be safe in situations where complete switching is necessary.  
I have envisioned a set of single-virus designs that combines the recombinase and 
the stable inversion switch within a single viral vector (Figure 5.2a). This design would 
ensure that all transduced cells contain both the stable inversion switch and the 
FlpOERT2. In addition, there is a potential advantage in that this design contains a self-
excising FlpOERT2 system, which may address challenges of immunogenicity by 
eventually removing the enzyme completely from the cell. Further work will be required 
to characterize the performance of these single-virus designs, but preliminary work with a 
single-virus OFF switch suggests that this design may be functional in T cells (Figure 
5.3b). It is possible that the single-virus design will display different dynamics compared 
to the double-virus system, which may be compounded by the larger number of 
parameters that can be adjusted in the single-virus. Such a result would be exciting, 
creating a wider toolbox for therapeutic design. 
Advancing 2-State and 4-State Circuits 
In addition, the circuits I described here only controlled expression of one CAR 
gene. However, there are clearly two slots in the switch cassette that can encode a gene, 
one for each state such as the mCherry/GFP switch used in previous chapters. One could 




CARs of different affinities, targets, or other properties (Figure 5.3a). While I have tried 
to program two CARs into this circuit using a lentiviral vector, I was unable to express 
this circuit in T cells. One likely explanation is that viral integration becomes 
increasingly inefficient as the size of the insert increases (109), and circuits that require 
the expression of several components can become large, making efficient transduction of 
these genes very challenging.  
This constraint is a major challenge for the advance of synthetic biology in 
general as it inhibits the ability to construct potentially large and complex circuits to 
control mammalian cells. Alternate approaches have emerged in the form of transposons, 
enzymes that are able to integrate large amounts of DNA between set sites in the genome. 
Transposons like PiggyBac, which integrates at TTAA sites, have no known size limit 
(61, 110), and some—such as Sleeping Beauty (111)—have been used to integrate CARs 
in clinical trials (36). Transposon-based integration strategies for T cells require transient 
transfection or nucleofection, which has posed a major practical hurdle in developing 
transposon-based circuits for primary T cells due to the challenge of implementing 
nucleofection protocols.  
With further work to develop nucleofection protocols and implement transposon-
based systems of integration, the possibilities for the circuit framework I have developed 
here can become as immense as whatever can be cloned into the transposon vector. For 
example, just as multiple recombinases have been used to design complex logic gates in 
HEK293 cells, advanced circuits could be designed in T cells by combining stable 




combine a 4OHT-inducible FlpO and a TMP-inducible PhiC to construct a combination 
of the expression level switch with the 2-CAR switch (Figure 5.3b). The product would 
be a 4-state switch that controls both what CAR is expressed and at what level. 
5.3 Conclusion 
The genetic circuits I have constructed will enable the development of more 
complex T cell therapeutics by providing a platform to program two different therapeutic 
states into a cell simply by expressing a particular gene of choice within the switch 
cassette. This increased complexity will expand the types of treatment strategies that can 
be implemented by creating a switch that can be altered at bedside to respond to a 
patient’s individual needs, programming multiple cell-based therapies into a single T cell. 
In addition, I have laid out a strategy for designing and testing circuit component 
candidates that takes into account the time, cost, and ease of running particular protocols 
in different cell types. This pipeline can advance the design of future genetic circuits in T 
cells by providing an approach that is faster than simply testing all potential components 
immediately in primary T cells.    
  While I have focused on its use with CARs in this work, these circuits are also 
compatible with other forms of T cell therapies that could benefit from control of other 
genes. T cell therapies will require us to not just rely on the mechanics of the immune 
system, but to understand the intricacies that are available and necessary for us to fine-
tune in order to create a safe and effective treatment. With many developments and tools 








Figure 5.1 Integrating other components into the stable inversion switch could increase the 
safety and use of these circuits for T cell therapies. 
(a) Designs using a T2a ribosomal skip sequence could add the iCasp9 rapamycin-inducible kill 
switch into the ON or OFF switch could help selectively kill cells whose behavior is not 
conforming to the needs of the patient, such as cells expressing incomplete switching in the OFF 
switch or cells exhibiting basal activity in the ON switch. This approach may help to target only a 
select population of misbehaving cells as opposed to shutting down the whole therapy. (b) These 
stable inversion switches are a platform that can be expanded to control expression of other genes 





Figure 5.2 Single-virus designs may provide a new platform to advance stable inversion 
switches by guaranteeing an increasingly homogenous population. 
(a) The design of switches expressing the inducible recombinase within the switch cassette could 
allow for easy implementation of all circuit components with one virus. (b) A single-virus OFF 
switch expressing an αHer2-CAR in Jurkat T cells exhibited OFF behavior within 11 days of 





Figure 5.3 The stable inversion switch design can be expanded to control expression of two 
genes and possibly even create a 4-state switch. 
(a) The stable inversion switch design could potentially accommodate two CAR genes, allowing 
switching between CARs of different properties or targets that further refine T cell behavior. (b) 
Developing other inducible recombinase-based stable inversion switches may provide a path 
towards creating a 4-state CAR switch that combines the expression level switch with the 2-CAR 
switch. Implementing designs with increasing complexity like (a) and (b) may depend upon the 







The circuit we described is comprised of two parts: the inducible recombinase and 
the FLEx switch. These components were cloned into separate lentiviral backbones using 
a combination of Gibson and traditional molecular cloning methods. The FlpOERT2 
recombinase was obtained from the Joyner lab and cloned into the backbone followed by 
a T2A ribosomal skip sequence and an mTAG-BFP fluorescent marker. 
The FLEx switch was designed using the frt and f3 recombination sites. For the 
ON and OFF switches, the chimeric antigen receptor sequence was inserted between the 
recombination sites. The SFFV promoter was used to drive FLEx switch (and thus, CAR) 
expression. For the expression level switch, the EF1α promoter was inserted between the 
recombination sites such that the reverse promoter orientation was encoded in the 5’ to 3’ 
direction. The CAR was expressed downstream of the FLEx/reverse EF1α promoter. 
HEK293T maintenance and transient transfection 
Human endothelial kidney (HEK) cells were maintained in Dulbecco’s Modified 
Eagle Medium (DMEM, Corning) supplemented with 10% fetal bovine serum (FBS), 
sodium pyruvate, glutamine, and penicillin. For transient transfection of inducible 
recombinase constructs, cells were plated overnight in 24 well plates at a density of 
200,000 cells/mL. Plasmids were transfected using polyethylenimine (PEI). The next day, 




were maintained one more day and then collected for measurement via flow cytometry. 
Jurkat T cell maintenance and transduction 
Through transduction and general maintenance, Jurkat T cells were maintained in 
RPMI media (Lonza) supplemented with 5% fetal bovine serum (Gibco), glutamine, and 
penicillin-streptomycin. Through analysis, cells were maintained in RPMI media 
supplemented with 10% fetal bovine serum and glutamine.  
Lentiviral transduction was used to produce T cell lines containing full circuitry 
(inducible recombinase and designated ON/OFF/EXP switch). Human endothelial kidney 
(HEK) cells were transfected via PEI in a 6 well plate with lentiviral packaging plasmids 
and the circuit component lentiviral plasmid to produce virus containing the specified 
component. Virus was collected three days after transfection. 
Approximately 500,000 Jurkat NFAT cells—a line produced by the Weiss lab at 
UCSF (92) to express an NFAT-GFP activation reporter—were infected with 500 uL of 
the recombinase virus and 500 uL of the switch for co-transduction of the entire circuit. 
Transduced Jurkat-NFAT cell were diluted with media one day after infection and then 
collected three days after infection. 
Primary T cell isolation and transduction 
Blood was obtained from the Boston Children’s Hospital, and primary CD4+ T 
cells were harvested using the STEMCELL CD4+ enriched cocktail in conjunction with 
the RosetteSep system. T cells were preserved at -80°C in 90% FBS (Gibco) and 10% 




Human AB Serum (Valley Biomedical), 10 mM N-acetyl L-Cyteine, and 55  M 2-
mercaptoethanol. Through thawing and transduction, T cells were maintained with 100 
units/mL IL2 and then 50 units/mL post-transduction. 
HEK cells were transfected with lentiviral packaging plasmids and either the 
FLEx switch plasmid or the inducible recombinase plasmid in a T175 flask using PEI. 
One day after transfection, media was replaced with Ultraculture media (Lonza) 
supplemented with Penicillin/Streptomycin, Glutamine, Sodium Butyrate, and Sodium 
Pyruvate, and virus was collected three and four days after transfection by collecting and 
spinning the media, and retaining the supernatant. Virus was concentrated through 
ultracentrifugation for two hours at 4 oC and 22,000xg.  
T cells were thawed two days prior to transduction and activated with CD3/CD28 
Dynabeads (Gibco) one day prior. Cells were transduced via spinfection: using half of 
concentrated virus, both inducible recombinase and switch viruses were spun onto the 
well of a 6-well retronectin-coated plates for 90 minutes at 1200xg. Activated primary T 
cells were then spun onto the virus plates for 60 minutes at 1,200xg. 
Switch Induction with 4OHT 
Cells were induced with 4-hydroxytamoxifen, a metabolite of tamoxifen, in 
methanol solution. All induction experiments were conducted with 1 uM 4OHT except 
for dose response experiments, which were conducted with a 4OHT concentration range 
from 10-5 to 10 uM. For induction time courses, cells were induced at a starting 
concentration of 200,000 cells/mL and maintained between 200,000-1,200,000 cells/mL 




the same concentrations in inducer-negative media.  
To test effect of induction duration, cells were induced at a starting concentration 
of 800,000 cells/mL. For each day up until 4 days post-induction, a fraction of induced 
cells were removed. Removed cells were then spun down, washed with 5 mL inducer-
negative media, and then resuspended to a concentration of 800,000 cells/mL in inducer-
negative media. Induced cells were then diluted 1:2. On day 4, all cells were diluted 1:8, 
and 8 days post-induction, one last batch of induced cells were washed. Through the rest 
of the experiment, cells were maintained between 200,000-1,600,000 cells/mL.  
CAR Activation with plate-bound Her2 protein 
Target antigen was plated on 96 well, tissue culture-treated flat bottom plates in 
phosphate buffered saline (PBS) for two hours at 37 oC. Wells were then washed two 
times with PBS, and 200,000 cells at a concentration of 1,000,000 cells/mL were plated 
overnight.  
Flow cytometry analysis 
CAR and NFAT-GFP expression were measured via flow cytometry (Attune NxT 
Flow Cytometer, Thermo Fisher Scientific). Results were analyzed using FlowJo 10.0.7 
(FlowJo, LLC). 
IL-2 ELISA 
IL-2 production by CD4+ primary T cells was measured using an ELISA kit (BD 
550611) according to manufacturer’s instruction. 100 ul of supernatant from each sample 
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